Vioxx And Merck & Co.

Vioxx/Merck

Summary

The painkiller Vioxx was introduced in 1999 by Merck & Co. It has been used by over 20 million Americans since it was put on the market. Vioxx remained on the market for approximately five years without adequate warnings about its risks. In September of 2004, Merck took Vioxx off the market after a study revealed that it doubled the risk of heart attack or stroke for patients that used it for more than 18 months. Although Merck claimed that they had no idea of these possibly lethal side effects, some internal documents imply that they had been aware of the problem for years and had not made moves to change it. Over 300 lawsuits have been filed against Merck, and it is expected that thousands more will arise.

Further studies were conducted on the drug, but Merck adamantly fought Vioxx findings. Even thou Merck funded and agreed with the design of the study, it publicly discredited its findings. Other reports showed that in older patients, Vioxx made no provide as much protection as it is expected to. One study links Vioxx to 88,000 to140,000 cases of heart disease. Most of this information had been kept private for quite a long time.

Despite the obvious health risks, in February of 2005, government advisers concluded that the benefits of Vioxx outweighed the dangers and that it was the patients decision whether or not to keep using the drugs. They stated that the prescription products should have strong warning, and advised that a long-term study be conducted to further understand the drug. However, 10 of the government drug advisers who supported the continuance of Vioxx were in some way tied financially to the drug. Without their votes, the committee would have voted that Vioxx should not return to the market.

Response

Personally, I was shocked by the Merck/Vioxx situation. I could not believe that something that was basically proven to cause heart attacks and strokes was permitted to be put on the market in the first